🚀 VC round data is live in beta, check it out!

Largest Biopharmaceuticals Public Companies in South Korea

Benchmark revenue and EBITDA valuation multiples for public comps like Celltrion, Alteogen, Samsung Bioepis, Samchundang Pharm and ABL Bio.

Reset all filters
South Korea
$136
+28%
$30B
$32B
10.4x
28.1x
South Korea
$250
+6%
$13B
$13B
64.5x
104.9x
South Korea
$350
--
$9B
$9B
7.4x
27.9x
South Korea
$341
+260%
$8B
$8B
—
—
South Korea
$105
+142%
$6B
$6B
93.7x
(49.1x)
South Korea
$66
-8%
$5B
$5B
9.6x
30.0x
South Korea
$63
-17%
$5B
$5B
3.1x
36.2x
South Korea
$122
+72%
$4B
$4B
38.0x
(82.0x)
South Korea
$185
+69%
$4B
$4B
—
—
South Korea
$330
+82%
$4B
$4B
4.0x
17.8x
South Korea
$191
+197%
$3B
$3B
—
—
South Korea
$29
+9%
$2B
$2B
4.3x
(16.7x)
South Korea
$46
+316%
$2B
$2B
179.6x
(100.5x)
South Korea
$169
-31%
$2B
$1B
4.8x
9.7x
South Korea
$38
+19%
$2B
$2B
—
—
South Korea
$32
+70%
$2B
$2B
15.1x
362.1x
South Korea
$35
+91%
$1B
$1B
20.3x
39.7x
South Korea
$100
+7%
$1B
$2B
1.6x
9.4x
South Korea
$33
+20%
$921M
$1B
1.6x
10.6x
South Korea
$10
+165%
$920M
$905M
—
—
South Korea
$12
+59%
$898M
$1B
—
—
South Korea
$35
+250%
$793M
$731M
142.4x
(933.7x)
South Korea
$59
+8%
$779M
$794M
0.7x
9.4x
South Korea
$12
+62%
$692M
$663M
7.7x
21.8x
South Korea
$34
+463%
$655M
$630M
—
—
South Korea
$14
+272%
$632M
$596M
—
—
South Korea
$71
-40%
$465M
$484M
2.9x
26.8x
South Korea
$9
-2%
$417M
$1B
—
—
South Korea
$41
+46%
$334M
$315M
25.6x
(520.2x)
South Korea
$7
-27%
$236M
$288M
2.4x
92.9x
South Korea
$19
+31%
$224M
$222M
—
—
South Korea
$5
-21%
$122M
$107M
—
—
South Korea
$2
-44%
$122M
$178M
—
—
South Korea
$5
-36%
$65M
$53M
—
—
South Korea
$2
-23%
$45M
$66M
—
—
South Korea
$2
-48%
$39M
$32M
10.5x
—

Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial